The approval makes Wegovy the first GLP-1 receptor agonist available in tablet form for weight management across all European Union member states
It follows a positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use in May 2026
European Commission Approves First Oral GLP-1 Therapy For Weight Management
The latest decision marks the fifth regulatory approval for the Wegovy pill after previous authorizations in the United States, the U.K., the United Arab Emirates, and Bahrain
The European Commission also approved the Wegovy 7.2 mg injection in a single-dose pen for obesity
Novo Nordisk said it plans to introduce the treatment in additional countries during the second half of 2026
Clinical Trial Data Show Significant Weight Loss With Oral Semaglutide
The approval was supported by the OASIS clinical trial program, including the OASIS 4 study, which evaluated once-daily oral semaglutide 25 mg in adults with obesity or overweight and at least one weight-related comorbidity
Novo Nordisk said the safety and tolerability profile of oral semaglutide was consistent with the established injectable version. Adverse event-related discontinuation rates were 6.9% for oral semaglutide compared with 5.9% for placebo
NVO Price Action: Novo Nordisk shares were up 2.52% at $50.30 at the time of publication on Wednesday
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred
